Neuronal progenitor cells-based metabolomics study reveals dysregulated lipid metabolism and identifies putative biomarkers for CLN6 disease

• Published in: Scientific reports Vol. 13; no. 1; pp. 18550 - 15
• Main Authors: Rus, Corina-Marcela, Polla, Daniel L., Di Bucchianico, Sebastiano, Fischer, Steffen, Hartkamp, Jörg, Hartmann, Guido, Alpagu, Yunus, Cozma, Claudia, Zimmermann, Ralf, Bauer, Peter
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.10.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/45; 692/53; 692/699; Biomarkers; Calcium metabolism; Calcium signalling; Humanities and Social Sciences; Lipid metabolism; Metabolism; Metabolites; Metabolomics; multidisciplinary; Mutation; Nervous system; Neural stem cells; Neuronal ceroid lipofuscinosis; Progenitor cells; Science; Science (multidisciplinary); Sphingolipids
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-45789-7

Neuronal ceroid lipofuscinosis 6 (CLN6) is a rare and fatal autosomal recessive disease primarily affecting the nervous system in children. It is caused by a pathogenic mutation in the CLN6 gene for which no therapy is available. Employing an untargeted metabolomics approach, we analyzed the metabolic changes in CLN6 subjects to see if this system could potentially yield biomarkers for diagnosis and monitoring disease progression. Neuronal-like cells were derived from human fibroblast lines from CLN6-affected subjects (n = 3) and controls (wild type, n = 3). These were used to assess the potential of a neuronal-like cell-based metabolomics approach to identify CLN6 distinctive and specific biomarkers. The most impacted metabolic profile is associated with sphingolipids, glycerophospholipids metabolism, and calcium signaling. Over 2700 spectral features were screened, and fifteen metabolites were identified that differed significantly between both groups, including the sphingolipids C16 GlcCer, C24 GlcCer, C24:1 GlcCer and glycerophospholipids PG 40:6 and PG 40:7. Of note, these fifteen metabolites were downregulated in the CLN6 disease group. This study is the first to analyze the metabolome of neuronal-like cells with a pathogenic mutation in the CLN6 gene and to provide insights into their metabolomic alterations. This could allow for the development of novel biomarkers for monitoring CLN6 disease.